AFFILIATIONS
1 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
2 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
3 Natera, Inc., Austin, Texas, United States
4 Natera, Inc., Austin, Texas, United States
5 Natera, Inc., Austin, Texas, United States
6 Natera, Inc., Austin, Texas, United States
7 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
8 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
9 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
10 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
11 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
12 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
13 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
14 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
15 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
16 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
17 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
ABSTRACT
Introduction: Chimeric antigen receptor T-cell (CAR-T) therapy is a highly effective immunotherapy for relapsed or refractory follicular lymphoma. However, biomarkers that can improve disease surveillance following treatment are increasingly needed. Here, we evaluate the association of circulating tumor DNA (ctDNA) for molecular residual disease (MRD) with relapse in patients with follicular lymphoma treated with a CD20-specific CAR T therapy.
Methods: Patients with relapsed follicular lymphoma who enrolled in a phase I/II dose-escalation study of CD20-specific CAR T therapy (NCT03277729) were included. Trial eligibility required progressive disease after ≥1 prior therapy. Personalized, tumor-informed ctDNA assays (Signatera™ Genome, Natera, Inc.) were designed from whole genome sequencing data of each patient's baseline/pretreatment tumor and matched normal tissue. Plasma samples were collected at screening (pretreatment), 28 days following CAR-T infusion, and 3 months post-infusion. The association between ctDNA-based MRD status or PET imaging at day 28 (D28) and cumulative incidence of relapse (CIR, with non-relapse death treated as a competing risk) was estimated using using the Fine-Gray subdistribution hazard model landmarked at D28 post infusion.
Results: A ctDNA assay was successfully developed in 18 of the 20 patients enrolled (n=49 timepoints). One patient’s tumor DNA was discordant from plasma DNA samples (potentially due to sample mislabeling) and was excluded. Another patient had data pending at the time of analysis. Among the 18 patients with ctDNA results, 11 (61%) were female, median age was 62 (range: 45-81) years, and median clinical follow-up was 45 months (range: 9-64). ctDNA testing was available prior to CAR-T infusion for 17/18 (94%) of patients, 100% (N=17/17) of whom had a positive baseline ctDNA result (median ctDNA levels: 240.15 mean tumor molecules [MTM]/mL, range: 3.84-2810 MTM/mL). Across all 32 post-treatment timepoints, 47% (n = 15) were ctDNA-MRD positive. At D28, 9 (53%) were ctDNA-MRD positive, of whom 6 (67%) developed clinical disease progression (median time to relapse: 6.21 months). The remaining 8 (47%) were ctDNA-MRD negative, of whom 1 (13%) experienced disease recurrence 8.6 months after the negative ctDNA timepoint. Accounting for non-relapse death as a competing risk, the 3-year CIR was 12.5% vs. 66.7% for ctDNA-MRD negative vs. positive patients (Fine-Gray subdistribution HR: 7.99, 95% CI: 1.16–54.9, p=0.035). At D28, 11 (61%) patients had a complete response by PET-CT and 7 had a positive PET-CT. Subsequent lymphoma progression was documented in 4 (36%) PET-negative patients and 4 (57%) PET-positive patients (Fine-Gray subdistribution HR: 2.59, 95% CI: 0.62-10.8, p=0.19). Across the 17 patients with both D28 ctDNA MRD and imaging available, results were concordant for 76% (N=13/17) patients (Fisher’s exact test p=0.0498). Among the 4 discordant cases, 3 were ctDNA-MRD positive/imaging negative and 1 was ctDNA-MRD negative/imaging positive. Of the 3 ctDNA-positive/imaging-negative patients, 2 subsequently relapsed with a lead time of 1.5 and 35 months, consistent with ctDNA-MRD detecting molecular disease prior to radiographic evidence. The third patient did not relapse; a follow-up ctDNA assessment 3 months later showed a >50% decline in ctDNA levels, suggesting this may have represented a transient or resolving signal rather than a false positive. The single ctDNA-negative/imaging-positive patient did not experience disease recurrence and died of COVID-19 9 months later, unrelated to the underlying malignancy.
Conclusion: Here, we found that ctDNA-MRD positivity was associated with clinical outcomes from CD20-specific CAR T therapy in patients with follicular lymphoma. While ctDNA-MRD and PET-CT results were concordant, ctDNA-MRD results were more often aligned with clinical outcomes.